Show simple item record

dc.contributor.authorAthauda, Aen_US
dc.contributor.authorWatkins, Den_US
dc.contributor.authorMohammed, Ken_US
dc.contributor.authorChau, Ien_US
dc.contributor.authorStarling, Nen_US
dc.contributor.authorRao, Sen_US
dc.contributor.authorTait, Den_US
dc.contributor.authorAitken, Ken_US
dc.contributor.authorCunningham, Den_US
dc.coverage.spatialGreeceen_US
dc.date.accessioned2018-11-14T12:15:16Z
dc.date.issued2018-10en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/30275223en_US
dc.identifier38/10/5943en_US
dc.identifier.citationAnticancer Res, 2018, 38 (10), pp. 5943 - 5949en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2936
dc.identifier.eissn1791-7530en_US
dc.identifier.doi10.21873/anticanres.12940en_US
dc.description.abstractBACKGROUND/AIM: Cisplatin-based radical chemoradiotherapy (CRT) is utilised in oesophagogastric (OG) cancer but the toxicity profile of cisplatin limits its use. This study aimed to evaluate the clinical characteristics and outcomes of patients treated with either cisplatin or carboplatin based CRT at our institution. MATERIALS AND METHODS: This is a retrospective analysis of patients with localised OG cancer undergoing CRT with cisplatin/fluoropyrimidine (CX/F) or carboplatin/fluoropyrimidine (CarboX/F) between January 2001 and December 2014. RESULTS: A total of 91 eligible patients were included. Median age was 65 years (IQR=57-75) for CX/F and 77 years (IQR=69-80) for CarboX/F. Adenocarcinoma histology and Charlson comorbidity index were higher in the CarboX/F group. Endoscopic complete response (CR) was achieved in 64% of CX/F group and 48% of CarboX/F group (p=0.19). The median PFS for CX/F was 31.0 months (95%CI=18.2-NE) vs. 18.7 months for CarboX/F (95%CI=13.5-30.4; HR=1.49, p=0.21). CONCLUSION: Despite significant differences in baseline clinical characteristics, patients treated with carboplatin CRT demonstrated no significant difference in PFS or endoscopic CR rate, compared to those treated with cisplatin.en_US
dc.format.extent5943 - 5949en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectPlatinumen_US
dc.subjectchemotherapyen_US
dc.subjectlocally advanceden_US
dc.subjectoesophageal canceren_US
dc.subjectradiotherapyen_US
dc.subjectAdenocarcinomaen_US
dc.subjectAgeden_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectCarboplatinen_US
dc.subjectCarcinoma, Squamous Cellen_US
dc.subjectChemoradiotherapyen_US
dc.subjectCisplatinen_US
dc.subjectEsophageal Neoplasmsen_US
dc.subjectEsophagogastric Junctionen_US
dc.subjectFemaleen_US
dc.subjectFluorouracilen_US
dc.subjectFollow-Up Studiesen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectPaclitaxelen_US
dc.subjectPrognosisen_US
dc.subjectRetrospective Studiesen_US
dc.subjectStomach Neoplasmsen_US
dc.subjectSurvival Rateen_US
dc.subjectTertiary Care Centersen_US
dc.titleCisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.en_US
dc.typeJournal Article
dcterms.dateAccepted2018-09-04en_US
rioxxterms.versionofrecord10.21873/anticanres.12940en_US
rioxxterms.licenseref.startdate2018-10en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfAnticancer Resen_US
pubs.issue10en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials/Gastrointestinal Cancers Clinical Trials (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume38en_US
pubs.embargo.termsNot knownen_US
icr.researchteamGastrointestinal Cancers Clinical Trialsen_US
icr.researchteamMedicine (RMH Smith Cunningham)en_US
dc.contributor.icrauthorCunningham, Daviden_US
dc.contributor.icrauthorChau, Ianen_US
dc.contributor.icrauthorStarling, Naureenen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record